{"pmid":32333712,"title":"SARS-CoV-2 Pandemic and The Need for Transplant-oriented Trials.","text":["SARS-CoV-2 Pandemic and The Need for Transplant-oriented Trials.","After the first reported case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan, China, in December 2019, the contagion has spread rapidly and has become a global pandemic.(1) There are as of yet no published studies beyond the case series describing the incidence and clinical course of COVID-19 in transplant recipients, a population potentially at high risk due to the ongoing immunosuppression and higher risk of comorbidities.(2) This pandemic has had a major impact in transplant physicians and healthcare workers as well(3) and this crisis has meant reducing or even interrupting transplant program activity, with a subsequent impact on patient morbidity and mortality that is still hard to quantify.","Transpl Int","Zaza, Gianluigi","Benedetti, Claudia","Fribourg, Miguel","Maggiore, Umberto","Azzi, Jamil","Riella, Leonardo V","Cravedi, Paolo","32333712"],"abstract":["After the first reported case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan, China, in December 2019, the contagion has spread rapidly and has become a global pandemic.(1) There are as of yet no published studies beyond the case series describing the incidence and clinical course of COVID-19 in transplant recipients, a population potentially at high risk due to the ongoing immunosuppression and higher risk of comorbidities.(2) This pandemic has had a major impact in transplant physicians and healthcare workers as well(3) and this crisis has meant reducing or even interrupting transplant program activity, with a subsequent impact on patient morbidity and mortality that is still hard to quantify."],"journal":"Transpl Int","authors":["Zaza, Gianluigi","Benedetti, Claudia","Fribourg, Miguel","Maggiore, Umberto","Azzi, Jamil","Riella, Leonardo V","Cravedi, Paolo"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333712","week":"202017|Apr 20 - Apr 26","doi":"10.1111/tri.13626","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1665071049674326017,"score":8.518259,"similar":[{"pmid":32277555,"title":"Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report.","text":["Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report.","An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in Wuhan, China, with cases now confirmed in multiple countries. The clinical course of patients remains to be fully characterized, clinical presentation ranges from asymptomatic infection to acute respiratory distress syndrome and acute renal failureno pharmacological therapies of proven efficacy yet exist. We report a case of SARS-CoV-2 infection in a renal transplant recipient with excellent outcome. This case states the importance of close monitoring of the concentration of ciclosporin in patients treated with lopinavir/ritonavir, routine treatment of corticosteroid can be continued. This is a rare report of SARS-CoV-2 infection in a renal transplant recipient. Further data are needed to achieve better understanding of the impact of immunosuppressive therapy on the clinical presentation, severity and outcome of SARS-CoV-2 infections in solid organ transplant recipients.","Am J Transplant","Ning, Ling","Liu, Lei","Li, Wenyuan","Liu, Hongtao","Wang, Jizhou","Yao, Ziqin","Zhang, Shengyu","Zhao, Desheng","Nashan, Bjorn","Shen, Aizong","Liu, Lianxin","Li, Lei","32277555"],"abstract":["An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in Wuhan, China, with cases now confirmed in multiple countries. The clinical course of patients remains to be fully characterized, clinical presentation ranges from asymptomatic infection to acute respiratory distress syndrome and acute renal failureno pharmacological therapies of proven efficacy yet exist. We report a case of SARS-CoV-2 infection in a renal transplant recipient with excellent outcome. This case states the importance of close monitoring of the concentration of ciclosporin in patients treated with lopinavir/ritonavir, routine treatment of corticosteroid can be continued. This is a rare report of SARS-CoV-2 infection in a renal transplant recipient. Further data are needed to achieve better understanding of the impact of immunosuppressive therapy on the clinical presentation, severity and outcome of SARS-CoV-2 infections in solid organ transplant recipients."],"journal":"Am J Transplant","authors":["Ning, Ling","Liu, Lei","Li, Wenyuan","Liu, Hongtao","Wang, Jizhou","Yao, Ziqin","Zhang, Shengyu","Zhao, Desheng","Nashan, Bjorn","Shen, Aizong","Liu, Lianxin","Li, Lei"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277555","week":"202015|Apr 06 - Apr 12","doi":"10.1111/ajt.15897","source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China","ciclosporin"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Cyclosporine","lopinavir-ritonavir drug combination"],"_version_":1664636943937306625,"score":174.02094},{"pmid":32317402,"title":"Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York.","text":["Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York.","BACKGROUND: The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes. METHODS: We report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes. RESULTS: Patients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up. CONCLUSIONS: Kidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed.","J Am Soc Nephrol","32317402"],"abstract":["BACKGROUND: The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes. METHODS: We report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes. RESULTS: Patients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up. CONCLUSIONS: Kidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed."],"journal":"J Am Soc Nephrol","date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317402","week":"202017|Apr 20 - Apr 26","doi":"10.1681/ASN.2020030375","keywords":["covid-19","epidemiology and outcomes","kidney transplantation","transplant outcomes"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","Azithromycin"],"_version_":1664815087718760448,"score":173.01846},{"pmid":32323460,"title":"Solid Organ Transplantation Programs Facing Lack of Empiric Evidence in the COVID-19 Pandemic: A By-proxy Society Recommendation Consensus Approach.","text":["Solid Organ Transplantation Programs Facing Lack of Empiric Evidence in the COVID-19 Pandemic: A By-proxy Society Recommendation Consensus Approach.","The ongoing SARS-CoV-2 pandemic has a drastic impact on national healthcare systems. Given the overwhelming demand of facility capacity, the impact on all healthcare sectors has to be addressed. Solid organ transplantation represents a field with a high demand on staff, intensive care units and follow-up facilities. The great therapeutic value of organ transplantation has to be weighed against mandatory constraints of healthcare capacities. In addition, the management of immunosuppressed recipients has to be reassessed during the ongoing COVID-19 pandemic. In addressing these crucial questions, transplant physicians are facing a total lack of scientific evidence. Therefore, the aim of this study was to offer an approach of consensus-based guidance, derived from individual information of 22 transplant societies. Key recommendations were extracted and the degree of consensus among different organizations was calculated. A high degree of consensus was found for temporarily suspending non-urgent transplant procedures and living donation programs. Systematic PCR-based testing of donors and recipients was broadly recommended. Additionally, more specific aspects (e.g., screening of surgical explant teams and restricted use of marginal donor organs) were included in our analysis. This study offers a novel approach on informed guidance for healthcare management when a priori no scientific evidence is available.","Am J Transplant","Ritschl, Paul Viktor","Nevermann, Nora","Wiering, Leke","Wu, Helen Hairun","Morodor, Philipp","Brandl, Andreas","Hillebrandt, Karl","Tacke, Frank","Friedersdorff, Frank","Schlomm, Thorsten","Schoning, Wenzel","Ollinger, Robert","Schmelzle, Moritz","Pratschke, Johann","32323460"],"abstract":["The ongoing SARS-CoV-2 pandemic has a drastic impact on national healthcare systems. Given the overwhelming demand of facility capacity, the impact on all healthcare sectors has to be addressed. Solid organ transplantation represents a field with a high demand on staff, intensive care units and follow-up facilities. The great therapeutic value of organ transplantation has to be weighed against mandatory constraints of healthcare capacities. In addition, the management of immunosuppressed recipients has to be reassessed during the ongoing COVID-19 pandemic. In addressing these crucial questions, transplant physicians are facing a total lack of scientific evidence. Therefore, the aim of this study was to offer an approach of consensus-based guidance, derived from individual information of 22 transplant societies. Key recommendations were extracted and the degree of consensus among different organizations was calculated. A high degree of consensus was found for temporarily suspending non-urgent transplant procedures and living donation programs. Systematic PCR-based testing of donors and recipients was broadly recommended. Additionally, more specific aspects (e.g., screening of surgical explant teams and restricted use of marginal donor organs) were included in our analysis. This study offers a novel approach on informed guidance for healthcare management when a priori no scientific evidence is available."],"journal":"Am J Transplant","authors":["Ritschl, Paul Viktor","Nevermann, Nora","Wiering, Leke","Wu, Helen Hairun","Morodor, Philipp","Brandl, Andreas","Hillebrandt, Karl","Tacke, Frank","Friedersdorff, Frank","Schlomm, Thorsten","Schoning, Wenzel","Ollinger, Robert","Schmelzle, Moritz","Pratschke, Johann"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323460","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15933","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664895932844474368,"score":169.93646},{"pmid":32315122,"title":"COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient.","text":["COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly infecting people worldwide, resulting in the infectious disease coronavirus disease 19 (COVID-19) that has been declared a pandemic. Much remains unknown about COVID-19, including its effects on solid organ transplant (SOT) recipients. Given their immunosuppressed state, SOT recipients are presumed to be at high risk of complications with viral infections such as SARS-CoV-2. Limited case reports in single SOT recipients, however, have not suggested a particularly severe course in this population. In this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite the presence of a number of risk factors for poor outcomes, had a relatively mild clinical course.","Am J Transplant","Hsu, Jeffrey J","Gaynor, Pryce","Kamath, Megan","Fan, Ashley","Al-Saffar, Farah","Cruz, Daniel","Nsair, Ali","32315122"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly infecting people worldwide, resulting in the infectious disease coronavirus disease 19 (COVID-19) that has been declared a pandemic. Much remains unknown about COVID-19, including its effects on solid organ transplant (SOT) recipients. Given their immunosuppressed state, SOT recipients are presumed to be at high risk of complications with viral infections such as SARS-CoV-2. Limited case reports in single SOT recipients, however, have not suggested a particularly severe course in this population. In this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite the presence of a number of risk factors for poor outcomes, had a relatively mild clinical course."],"journal":"Am J Transplant","authors":["Hsu, Jeffrey J","Gaynor, Pryce","Kamath, Megan","Fan, Ashley","Al-Saffar, Farah","Cruz, Daniel","Nsair, Ali"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315122","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15936","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664714520019337216,"score":168.14597},{"pmid":32277387,"title":"Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","text":["Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.","Hepatol Int","Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George","32277387"],"abstract":["Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic."],"journal":"Hepatol Int","authors":["Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277387","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10043-z","keywords":["2019-ncov","covid-19","liver transplantation","management"],"source":"PubMed","topics":["Prevention","Diagnosis","Treatment"],"weight":1,"locations":["Beijing","China","Beijing"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636943894315008,"score":159.62683}]}